Dyadic International (NASDAQ:DYAI) Major Shareholder Francisco Trust Under Agreemen Sells 25,281 Shares

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 25,281 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $1.87, for a total value of $47,275.47. Following the sale, the insider directly owned 3,496,907 shares of the company’s stock, valued at approximately $6,539,216.09. This trade represents a 0.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Dyadic International Price Performance

NASDAQ:DYAI opened at $0.94 on Monday. Dyadic International Inc. has a 52 week low of $0.65 and a 52 week high of $1.35. The stock’s fifty day moving average is $0.77 and its two-hundred day moving average is $0.83. The company has a market capitalization of $34.27 million, a P/E ratio of -4.09 and a beta of 1.15. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The business had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. Equities analysts expect that Dyadic International Inc. will post 0.13 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $3.00.

Institutional Trading of Dyadic International

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International in the third quarter valued at $190,000. Marathon Capital Management acquired a new stake in shares of Dyadic International in the third quarter valued at $41,000. Apis Capital Advisors LLC purchased a new stake in shares of Dyadic International in the 3rd quarter valued at $1,817,000. Finally, Geode Capital Management LLC raised its holdings in shares of Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the period. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.